FDA Extends Exclusivity for Certain Combo-Meds

What’s two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing–and the wording–are bound to be controversial.


Gambro Acquisition Fuels Baxter’s Growth Before Split

The acquisition of dialysis company Gambro last September continues to fuel Baxter International’s ($BAX) sales growth as it preps to spin out its biopharma division in 2015. But despite some stop-gap measures, it’s not likely that Baxter will actually be able to meet the demand for its dialysis products until additional manufacturing capacity opens up in 2016.


Health IT VC Funding Drops in Q3

Mercom Capital Group, llc, a global communications and consulting firm, today released its report on funding and mergers and acquisitions (M&A) activity in the Healthcare Information Technology (IT) sector for the third quarter of 2014. Mercom’s comprehensive report covers deals of all sizes in Healthcare IT across the globe.


NIH Launches Big Data to Knowledge Center of Excellence

National Institutes of Health director Dr. Francis Collins today announced a new national initiative, the National Center of Excellence for Mobile Sensor Data-to-Knowledge (MD2K), focused on developing computational tools to facilitate the collection and analysis of large-scale health data generated by mobile and wearable sensors. Computer scientists Deepak Ganesan and Benjamin Marlin will co-lead the…

man woman hands holding broken heart

Are Shire and AbbVie on the Outs?

Following Shire plc’s (“Shire”) waiver of the three-day notice period, AbbVie Inc. (“AbbVie”) (NYSE: ABBV) announces today its Board of Directors’ withdraws its recommendation made on July 18, 2014 regarding the proposed Shire transaction and recommends that stockholders vote against the transaction.

Copyright © 2014 WhiteCityNews, All rights reserved.